Cinaciguat

Cinaciguat
Cinaciguat
Systematic (IUPAC) name
4-({(4-carboxybutyl)[2-(2-{[4-(2-phenylethyl)
phenyl]methoxy}phenyl)ethyl]amino}methyl)
benzoic acid
Clinical data
Pregnancy cat.  ?
Legal status  ?
Routes intravenous (?)
Identifiers
CAS number 329773-35-5
ATC code None
UNII 59K0Y58UAD YesY
Chemical data
Formula C36H39NO5 
Mol. mass 565.697 g/mol
SMILES eMolecules & PubChem
 YesY(what is this?)  (verify)

Cinaciguat (BAY 58-2667) is an experimental drug for the treatment of acute decompensated heart failure.

Mechanism of action

Cinaciguat activates the soluble guanylate cyclase (sGC) which is a receptor for nitric oxide. This increases biosynthesis of cyclic GMP, resulting in vasodilation.[1]

See also

  • Riociguat, another drug stimulating sGC, but with a different mechanism
  • PDE5 inhibitors act further downstream in the nitric oxide signalling pathway, reducing cyclic GMP degradation.

References

  1. ^ Schubert-Zsilavecz, M, Wurglics, M, Neue Arzneimittel 2009


Stub icon This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.